Table 2 Tumour mucinous differentiation and disease-free survival in patients with stage II/III CRC.

From: Tumour infiltrating lymphocyte status is superior to histological grade, DNA mismatch repair and BRAF mutation for prognosis of colorectal adenocarcinomas with mucinous differentiation

 

Cases/events

HR

95% CI

P value

 

1458/336

   

Mucinous vs. non-mucinous

 

0.80

0.59–1.09

0.163

Mucinous component vs. non-mucinous

 

0.82

0.58–1.16

0.260

Mucin component vs. mucinous

 

1.02

0.67–1.54

0.929

Age (decades)

 

0.97

0.88–1.07

0.559

Gender (female vs. male)

 

0.82

0.66–1.02

0.081

Tumour stage (III vs. II)

 

3.55

2.66–4.74

<0.001*

Site (right vs. left)

 

1.03

0.81–1.31

0.810

Grade (high vs. low)

 

1.73

1.37–2.19

<0.001*

MMR status (dMMR vs. pMMR)

 

0.53

0.38–0.74

<0.001*

BRAF status (mutated vs. wild-type)

 

1.48

1.07–2.05

0.017*

Adjuvant chemotherapy (yes vs. no)

 

0.65

0.49–0.86

0.003*

  1. Data are for multivariate analysis adjusted for baseline clinico-molecular variables.
  2. HR hazard ratio, CI confidence interval, dMMR DNA mismatch repair deficient, pMMR DNA mismatch repair proficient.
  3. *p  <  0.05.
Back to article page